Selby Nicholas M, Korrodi-Gregório Luís, Casula Anna, Kolhe Nitin V, Arbonés Daniel Ribes, Bukieda Katelyn D, Sahu Deepak, Rao Chris, Basadonna Giacomo
Centre for Kidney Research and Innovation, School of Medicine, University of Nottingham, UK.
Department of Renal Medicine, University Hospitals of Derby and Burton National Health Service Foundation Trust, Derby, UK.
Kidney Int Rep. 2020 Dec 16;6(3):636-644. doi: 10.1016/j.ekir.2020.12.004. eCollection 2021 Mar.
Acute kidney injury (AKI) is associated with increased health care utilization and higher costs. The Tackling AKI study was a multicenter, pragmatic, stepped-wedge cluster randomized trial that demonstrated a reduced hospital length of stay after implementation of a multifaceted AKI intervention (e-alerts, care bundle, and an education program). We tested whether this would result in cost savings.
A decision-analytic tree model from the payer perspective (National Health Service in the United Kingdom) was generated on which cost-effectiveness analyses were performed using a probabilistic sensitivity analysis, accounting only for direct medical costs. Clinical data from the Tackling AKI study were used as inputs and economic and utility data derived from relevant published literature.
A total of 24,059 AKI episodes occurred during the study period, and in 18,887 admissions the patient was discharged alive. When all AKI stages were considered together, the cost per AKI admission was £5065 in the control arm and £4333 in the intervention arm, representing an incremental cost saving of £732 per admission with the intervention. Similar results were obtained when AKI stages were included as separate variables. Costs per quality-adjusted life year were £61,194 in the control group and £51,161 in the intervention group. At a willingness to pay threshold of £20,000 per quality-adjusted life year, the probability of the intervention being cost-effective compared with standard care was 90%.
An organizational level approach to improve standards of AKI care reduces the cost of hospital admissions and is cost effective within the National Health Service in the United Kingdom.
急性肾损伤(AKI)与医疗保健利用率增加及成本升高相关。“应对AKI”研究是一项多中心、实用、阶梯式楔形整群随机试验,该试验表明实施多方面的AKI干预措施(电子警报、护理包和教育项目)后住院时间缩短。我们测试了这是否会带来成本节约。
从支付方(英国国家医疗服务体系)的角度生成了一个决策分析树模型,并使用概率敏感性分析进行成本效益分析,仅考虑直接医疗成本。“应对AKI”研究的临床数据用作输入数据,经济和效用数据则来源于相关的已发表文献。
在研究期间共发生了24,059例AKI事件,在18,887例入院病例中患者存活出院。当将所有AKI阶段综合考虑时,对照组中每例AKI入院的成本为5065英镑,干预组为4333英镑,这表明干预措施使每次入院的成本节约增加了732英镑。将AKI阶段作为单独变量纳入分析时也获得了类似结果。对照组中每质量调整生命年的成本为61,194英镑,干预组为51,161英镑。在每质量调整生命年支付意愿阈值为20,000英镑时,与标准护理相比,干预措施具有成本效益的概率为90%。
一种提高AKI护理标准的组织层面方法可降低住院成本,且在英国国家医疗服务体系内具有成本效益。